CEO Dr. Nader Pourhassan of CytoDyn Inc. (OTCQB: CYDY), returns to Stock Day to talk about plans to eventually move up to the NASDAQ, revolutionizing cancer treatment, and approaching revenues by 2020.

Colon Cancer # humanized monoclonal antibodies # less frequent dosing # minimal side effects # protects healthy cells # treatment and prevention of HIV #Pro 140